Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 11, Issue 9, 2009, Pages 891-899

  Kawamori, Ryuzo ^a   Kadowaki, T ^b   Ishii, H ^c   Iwasaki, M ^d   Iwamoto, Y ^e  

^a JUNTENDO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TENRI HOSPITAL   (Japan)

^d SEIKEI UNIVERSITY   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

HbA1c; Insulin glulisine; Type 1 diabetes mellitus

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO;

ADULT; ARTICLE; BEDTIME DOSAGE; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC COMA; INSULIN DEPENDENT DIABETES MELLITUS; INTERVERTEBRAL DISK HERNIA; JAPANESE; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; SEIZURE;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; JAPAN; MALE; MIDDLE AGED; PATIENT SATISFACTION; YOUNG ADULT;

EID: 69249231068     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01086.x     Document Type: Article

References (34)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994; 125: 177-188.
3. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381-389. Erratum in: N Engl J Med 2000; 342: 1376.
4. Heinemann L, Heise T, Jorgensen LN, Starke AA. Action profile of the rapid acting insulin analogue: Human insulin B28Asp. Diabet Med 1993; 10: 535-539.
5. Becker RH. Insulin glulisine complementing basal insulins: A review of structure and activity. Diabetes Technol Ther 2007; 9: 109-121.
6. Becker RH, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008; 47: 7-20.
7. Rave K, Klein O, Frick AD, Becker RH. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care 2006; 29: 1812-1817.
8. Heise T, Nosek L, Spitzer H et al. Insulin glulisine: A faster onset of action compared with insulin lispro. Diabetes Obes Metab 2007; 9: 746-753.
9. Gerich J, Becker RH, Zhu R, Bolli GB. Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine. Diabetes Technol Ther 2006; 8: 237-243.
10. Dreyer M, Prager R, Robinson et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 2005; 37: 702-707.
11. Garg SK, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: Insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract 2005; 11: 11-17. Erratum in: Endocr Pract 2005; 11: 145.
12. Kamal AD, Bain SC. Insulin glulisine: Efficacy and safety compared with other rapid-acting insulin analogues. Expert Opin Drug Saf 2007; 6: 5-7.
13. Bradley C, Lewis KS. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet Med 1990; 7: 445-451.
14. Bradley C. The Diabetes Treatment Satisfaction Questionnaire. In: Bradley C. ed. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Chur, Switzerland: Harwood Academic Publishers, 1994; 111-132.
15. Howorka K, Pumprla J, Schlusche C, Wagner-Nosiska D, Schabmann A, Bradley C. Dealing with ceiling baseline treatment satisfaction level in patients with diabetes under flexible, functional insulin treatment: assessment of improvements in treatment satisfaction with a new insulin analogue. Qual Life Res 2000; 9: 915-930.
16. Bott U, Ebrahim S, Hirschberger S, Skovlund SE. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabet Med 2003; 20: 626-634.
17. Bradley C, Witthaus E, Stewart J. Treatment satisfaction and psychological well-being in patients with type 1 diabetes treated with a new long-acting insulin glargine. Diabetes 1998; 48: A353.
18. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes. Diabet Med 2001; 18: 619-625.
19. Ashwell SG, Bradley C, Stephens JW, Withaus E, Home PD. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. Diabetes Care 2008; 31: 1112-1117.
20. Japan Diabetes Society. Treatment Guide for Diabetes 2008-2009. Tokyo, Japan: Bunkodo Co. Ltd, 2008.
21. Bradley C, Gamsu DS. Guidelines for encouraging psychological well-being: Report of a Working Group of the World Health Organization Regional Office for Europe and International Diabetes Federation European Region St Vincent Declaration Action Programme for Diabetes. Diabet Med 1994; 11: 510-516.
22. Ishii H, Bradley C, Riazi A, Barendse S, Yamamoto T. The Japanese version of the Diabetes Treatment Satisfaction Questionnaire (DTSQ): translation and clinical evaluation. Igaku no Ayumi 2000; 192: 809-814.
23. Shima K, Endo J, Oimomi M et al. Interim report of the Committee on the Standardization of glycated haemoglobin. Diabetes 1994; 37: 233-243.
24. Shima K, Endo J, Oimomi M et al. Report of the Committee on the Standardization of glycated haemoglobin. Diabetes 1994; 37: 855-864.
25. Kawamori R, Iwamoto Y, Kadowaki T, Iwasaki M. Comparison of efficacy between insulin glargine and NPH human insulin in type 1 diabetes patients undergoing intensive insulin treatment-phase II/III clinical studies in Japan. Rinshou Iyaku 2003; 19: 423-444.
26. Kawamori R, Iwamoto Y, Kadowaki T, Iwasaki M. Efficacy and safety of insulin glargine in concurrent use with oral hypoglycaemic agents for the treatment of type 2 diabetic patients. Rinshou Iyaku 2003; 19: 445-464.
27. Becker RH, Frick AD, Burger F, Potgieter JH, Scholtz H. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 2005; 113: 435-443.
28. Shalitin S, Phillip M. The role of new technologies in treating children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2007; 8 (Suppl. 6): 72-79.
29. Craig ME, Jones TW, Silink M, Ping YJ. Diabetes care, glycemic control, and complications in children with type 1 diabetes from Asia and the Western Pacific Region. J Diabetes Complications 2007; 21: 280-287.
30. Sima AA, Kamiya H, Li ZG. Insulin, C-peptide, hyperglycemia, and central nervous system complications in diabetes. Eur J Pharmacol 2004; 490: 187-197.
31. Gill GV, Huddle KR, Monkoe G. Long-term (20 years) outcome and mortality of type 1 diabetic patients in Soweto, South Africa. Diabet Med 2005; 22: 1642-1646.
32. Schernthaner G, Wein W, Sandholzer K, Equiluz-Bruck S, Bates PC, Birkett MA. Postprandial insulin lispro. A new therapeutic option for type 1 diabetic patients. Diabetes Care 1998; 21: 570-573.
33. Puder JJ, Endrass J, Moriconi N, Keller U. How patients with insulin-treated type 1 and type 2 diabetes view their own and their physician's treatment goals. Swiss Med Wkly 2006; 136: 574-580.
34. Kotsanos JG, Vignati L, Huster W et al. Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy. Diabetes Care 1997; 20: 948-958.